Meeting
2020 ASCO Virtual Scientific Program
Phase I study of regorafenib and sildenafil in advanced solid tumors.
Authors
Andrew Stewart Poklepovic
VCU Massey Cancer Center, Richmond, VA
Andrew Stewart Poklepovic , Sarah W. Gordon , William P. McGuire , Leroy R. Thacker II, Xiaoyan Deng , Mary Beth Tombes , Ellen Shrader , Alison A. Ryan , Maciej Kmieciak , Paul Dent
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
New Targets and New Technologies (non-IO)
Clinical Trial Registration Number
NCT02466802
Citation
J Clin Oncol 38: 2020 (suppl; abstr 3593)
DOI
10.1200/JCO.2020.38.15_suppl.3593
Abstract #
3593
Poster Bd #
323
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Interim results of a first-in-human phase 1 study of Q-1802, a CLDN18.2/PD-L1 bsABs, in patients with relapsed or refractory solid tumors.
First Author: Wang Yk
Poster
2022 ASCO Annual Meeting
NCI 9938: Phase I clinical trial of ATR inhibitor berzosertib (M6620, VX-970) in combination with irinotecan in patients with advanced solid tumors.
First Author: Liza C Villaruz
Poster
2022 ASCO Annual Meeting
A phase I trial of elimusertib in combination with cisplatin or with cisplatin plus gemcitabine in advanced solid tumors with an emphasis on urothelial carcinoma.
First Author: Ryan Leibrandt
Poster
2020 ASCO Virtual Scientific Program
Phase I study of the combination of alisertib (MLN8237) and gemcitabine in advanced solid tumors.
First Author: Jasmine Huynh